Skip to content

维拉斯特姆肿瘤

US · VSTM #3468 按市值排名
8.65 -0.58 -6.28%
实时 - 追踪5344个代码 - 心跳于116秒前 · 2026-10-16 20:02

最新新闻

  • 评级变动
    BTIG Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $18
    \u5e02\u573a\u8d44\u8baf · 2026/5/8
  • 评级变动
    Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $16
    \u5e02\u573a\u8d44\u8baf · 2026/4/16
  • 评级变动
    Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $14
    \u5e02\u573a\u8d44\u8baf · 2026/5/13
  • 公司公告
    Verastem: Verastem, Inc. - Reverse Split Option Symbol: VSTM New Symbol: VSTM1
    OCC · 2023/5/31
  • 评级变动
    Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $13
    \u5e02\u573a\u8d44\u8baf · 2026/8/11
  • 评级变动
    H.C. Wainwright Keeps Their Buy Rating on Verastem (VSTM)
    TipRanks · 2026/5/8
  • 评级变动
    Verastem (VSTM) Receives a Buy From B. Riley Securities
    TipRanks · 2026/5/22
  • RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $14
    \u5e02\u573a\u8d44\u8baf · 2026/9/18
  • 评级变动
    A Quick Look at Today's Ratings for Verastem(VSTM.US), With a Forecast Between $12 to $18
    \u5e02\u573a\u8d44\u8baf · 2026/8/7
  • 评级变动
    BTIG Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $19
    \u5e02\u573a\u8d44\u8baf · 2026/4/21
  • BTIG Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $18
    \u5e02\u573a\u8d44\u8baf · 2026/10/5
  • RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $14
    \u5e02\u573a\u8d44\u8baf · 2026/7/7
  • 评级变动
    Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $14
    \u5e02\u573a\u8d44\u8baf · 2026/6/18
  • 评级变动
    Analysts Offer Insights on Healthcare Companies: Atai Beckley N.V. (ATAI), Madrigal Pharmaceuticals (MDGL) and Verastem (VSTM)
    TipRanks · 2026/6/24
  • 评级变动
    H.C. Wainwright Sticks to Their Buy Rating for Verastem (VSTM)
    TipRanks · 2026/5/27
  • H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $18
    \u5e02\u573a\u8d44\u8baf · 2026/10/5
  • 评级变动
    RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $15
    \u5e02\u573a\u8d44\u8baf · 2026/5/8
  • Wolfe Research Maintains Verastem(VSTM.US) With Buy Rating
    \u5e02\u573a\u8d44\u8baf · 2026/9/17
  • 评级变动
    A Quick Look at Today's Ratings for Verastem(VSTM.US), With a Forecast Between $14 to $18
    \u5e02\u573a\u8d44\u8baf · 2026/6/25
  • 评级变动
    A Quick Look at Today's Ratings for Verastem(VSTM.US), With a Forecast Between $8 to $18
    \u5e02\u573a\u8d44\u8baf · 2026/6/24

新闻标题为自动聚合内容,未经我们团队独立核实或编辑。

报价时间 2026-10-16 20:02:22 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

维拉斯特姆肿瘤 讨论区 0 条评论

发表评论